JP2022515248A - 新規なサリチル酸誘導体、その医薬的に許容される塩、その組成物及びその使用方法 - Google Patents

新規なサリチル酸誘導体、その医薬的に許容される塩、その組成物及びその使用方法 Download PDF

Info

Publication number
JP2022515248A
JP2022515248A JP2021536402A JP2021536402A JP2022515248A JP 2022515248 A JP2022515248 A JP 2022515248A JP 2021536402 A JP2021536402 A JP 2021536402A JP 2021536402 A JP2021536402 A JP 2021536402A JP 2022515248 A JP2022515248 A JP 2022515248A
Authority
JP
Japan
Prior art keywords
cancer
group
compound
stat3
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021536402A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022515248A5 (https=
Inventor
トーマス ガンニング パトリック
アーマー シアウォッシュ
ローザ デイビッド
ティン ギャリー
ジレトゥー ムル
ソン パク チ
ディー．デ アロウジョ エルビン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Toronto
Original Assignee
University of Toronto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Toronto filed Critical University of Toronto
Publication of JP2022515248A publication Critical patent/JP2022515248A/ja
Publication of JP2022515248A5 publication Critical patent/JP2022515248A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/603—Salicylic acid; Derivatives thereof having further aromatic rings, e.g. diflunisal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2021536402A 2018-12-21 2019-12-20 新規なサリチル酸誘導体、その医薬的に許容される塩、その組成物及びその使用方法 Pending JP2022515248A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862783741P 2018-12-21 2018-12-21
US62/783,741 2018-12-21
PCT/CA2019/051884 WO2020124262A1 (en) 2018-12-21 2019-12-20 New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof

Publications (2)

Publication Number Publication Date
JP2022515248A true JP2022515248A (ja) 2022-02-17
JP2022515248A5 JP2022515248A5 (https=) 2022-12-28

Family

ID=71100034

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021536402A Pending JP2022515248A (ja) 2018-12-21 2019-12-20 新規なサリチル酸誘導体、その医薬的に許容される塩、その組成物及びその使用方法

Country Status (6)

Country Link
US (1) US20220089531A1 (https=)
EP (1) EP3898582A4 (https=)
JP (1) JP2022515248A (https=)
CN (1) CN113661158A (https=)
CA (1) CA3124267A1 (https=)
WO (1) WO2020124262A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3174623A1 (en) * 2020-03-05 2021-09-10 Janpix, Ltd. Stat inhibitory compounds and compositions
EP4114371A4 (en) * 2020-03-05 2024-04-17 Centessa Pharmaceuticals (UK) Limited ALPHA-SUBSTITUTED STAT INHIBITORS AND COMPOSITIONS THEREOF
TW202227398A (zh) * 2020-09-04 2022-07-16 英商詹皮克斯有限公司 Stat抑制性化合物及組合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017517521A (ja) * 2014-05-30 2017-06-29 ザ ガバニング カウンシル オブ ザ ユニバーシティ オブ トロント スルホンアミド化合物およびそのｓｔａｔ５阻害剤としての使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007136858A2 (en) * 2006-05-19 2007-11-29 H. Lee Moffitt Cancer Center & Research Institute Small molecule inhibitors of stat3 with anti-tumor activity
CN103608010A (zh) * 2010-08-02 2014-02-26 中央佛罗里达大学研究基金公司 作为stat蛋白的抑制剂的取代的2-羟基-4-(2-(苯基磺酰氨基)乙酰氨基)苯甲酸类似物
CN102219755B (zh) * 2011-05-05 2013-04-03 南京大学 Stat3的小分子选择性抑制剂及其制备方法和应用
CN110003104A (zh) * 2012-05-25 2019-07-12 多伦多大学管理委员会 水杨酸衍生物、其药学上可接受的盐、其组合物以及其使用方法
WO2014070859A1 (en) * 2012-10-30 2014-05-08 H. Lee Moffitt Cancer Center And Research Institute, Inc. Stat3 dimerization inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017517521A (ja) * 2014-05-30 2017-06-29 ザ ガバニング カウンシル オブ ザ ユニバーシティ オブ トロント スルホンアミド化合物およびそのｓｔａｔ５阻害剤としての使用

Also Published As

Publication number Publication date
US20220089531A1 (en) 2022-03-24
EP3898582A4 (en) 2022-08-24
CA3124267A1 (en) 2020-06-25
WO2020124262A1 (en) 2020-06-25
CN113661158A (zh) 2021-11-16
EP3898582A1 (en) 2021-10-27

Similar Documents

Publication Publication Date Title
JP6543366B2 (ja) 新しいサリチル酸誘導体、薬学上許容可能なその塩、その組成物及びその使用方法
JP6122006B2 (ja) ヒストン脱メチル化酵素阻害剤としての、置換された（ｅ）−ｎ’−（１−フェニルエチリデン）ベンゾヒドラジド類似体
JP2021533110A (ja) 癌免疫療法剤としての新規エクトヌクレオチドピロホスファターゼ／ホスホジエステラーゼ−１（ＥＮＰＰ１）の置換３Ｈ−イミダゾ［４，５−ｃ］ピリジンおよび１Ｈ−ピロロ［２，３−ｃ］ピリジンシリーズならびにインターフェロン遺伝子刺激因子（ＳＴＩＮＧ）調節剤
US10954258B2 (en) STAT3 dimerization inhibitors
JP2016523256A (ja) ヒストン脱メチル化酵素阻害剤としての置換（ｅ）−ｎ’−（１−フェニルエチリデン）ベンゾヒドラジド類似体
JP2012097090A (ja) 強力な抗糖尿病薬化合物の塩および多形体
KR20130121818A (ko) Stat 단백질의 저해제로서의 치환된 2-히드록시-4-(2-(페닐설폰아미도)아세트아미도)벤조산 유사체
TW202012375A (zh) 過氧化物酶體增生劑活化之受體（ppar）促效劑其化合物其醫藥組合物及其使用方法
CN108463222B (zh) 用于治疗疾病的杂环化合物
JP2022515248A (ja) 新規なサリチル酸誘導体、その医薬的に許容される塩、その組成物及びその使用方法
CN115703761A (zh) 作为wwp1抑制剂的化合物及其应用
JP2023504468A (ja) 焦点接着キナーゼ阻害剤としての新規なアダマンタン誘導体
CN112533917A (zh) 作为vps34的抑制剂的吗啉衍生物
HK40063807A (en) New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
US20250109154A1 (en) Lysophosphatidylserine analogue, and lysophosphatidylserine analogue-containing phamaceutical composition for treating or preventing fibrosis
RU2803116C2 (ru) Хинолинил-содержащее соединение и его фармацевтическая композиция и применение
WO2019179362A1 (zh) 脒类和胍类衍生物、其制备方法及其在医药上的应用
HK40070316A (en) Heterocyclic compounds for the treatment of disease
WO2024099403A1 (zh) 一种具有软药性质的硫醚类化合物、药物组合物及其用途
WO2019141095A1 (zh) 脒类和胍类衍生物、其制备方法及其在医药上的应用
HK1260375A1 (en) Heterocyclic compounds for the treatment of disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221220

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20221220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230331

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231114

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240611